If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery time. The Evaluate Vantage team has produced its round up of the investment and financial side of the industry and the results make for interesting – if sobering – reading.

Register now to receive your copy.



Outside big pharma, life remains tough for listed developers
First-quarter biotech risers work hard for the win
Takeover-driven resurgence fails to materialise for biotech
Flotations tank in the first quarter
Venture funding stays strong despite the gloom